Telephone
61.2.8315.7003
Address
Level 32, Suite 32.07 264 George Street Australia Square Sydney, New South Wales (NSW) 2000
Description
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987, and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.23 - 0.48
Trade Value (12mth)
AU$215,769.00
1 week
-2.47%
1 month
36.21%
YTD
15.55%
1 year
39.88%
All time high
4.07
EPS 3 yr Growth
-29.20%
EBITDA Margin
N/A
Operating Cashflow
-$35m
Free Cash Flow Return
-21.20%
ROIC
-26.00%
Interest Coverage
-1,573.40
Quick Ratio
18.20
Shares on Issue (Fully Dilluted)
1216m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.22
Date | Announcements |
---|---|
30 August 24 |
Appendix 4E & 2024 Full Year Statutory Accounts
×
Appendix 4E & 2024 Full Year Statutory Accounts |
21 August 24 |
Immutep Corporate Presentation
×
Immutep Corporate Presentation |
20 August 24 |
TACTI-003 data selected for oral presentation at ESMO 2024
×
TACTI-003 data selected for oral presentation at ESMO 2024 |
14 August 24 |
First Participant Dosed in Phase I Study of IMP761
×
First Participant Dosed in Phase I Study of IMP761 |
07 August 24 |
Immutep to Participate in Upcoming Investor Conferences
×
Immutep to Participate in Upcoming Investor Conferences |
31 July 24 |
Immutep Quarterly Activities Report and Appendix 4C
×
Immutep Quarterly Activities Report and Appendix 4C |
26 July 24 |
Change in substantial holding
×
Change in substantial holding |
22 July 24 |
Successful Meeting with FDA on Phase III Design in NSCLC
×
Successful Meeting with FDA on Phase III Design in NSCLC |
17 July 24 |
Regulatory Clearance received for Phase 1 trial of IMP761
×
Regulatory Clearance received for Phase 1 trial of IMP761 |
12 July 24 |
Webcast to discuss data presented at ESMO Plenary Session
×
Webcast to discuss data presented at ESMO Plenary Session |
12 July 24 |
Positive results in TACTI-003 for 1L HNSCC cohort B patients
×
Positive results in TACTI-003 for 1L HNSCC cohort B patients |
12 July 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
04 July 24 |
Change in substantial holding
×
Change in substantial holding |
03 July 24 |
Details for Immutep Webcast & ESMO Virtual Plenary Session
×
Details for Immutep Webcast & ESMO Virtual Plenary Session |
27 June 24 |
Positive topline results from ph2b in head & neck cancer
×
Positive topline results from ph2b in head & neck cancer |
27 June 24 |
Webcast slides for new Efti clinical data in 1st line HNSCC
×
Webcast slides for new Efti clinical data in 1st line HNSCC |
25 June 24 |
Immutep signs agreement for anti-LAG-3 small molecules
×
Immutep signs agreement for anti-LAG-3 small molecules |
25 June 24 |
Application for quotation of securities - IMM
×
Application for quotation of securities - IMM |
24 June 24 |
Immutep completes underwritten retail entitlement offer
×
Immutep completes underwritten retail entitlement offer |
18 June 24 |
Change in substantial holding from IFL
×
Change in substantial holding from IFL |
14 June 24 |
Change in substantial holding
×
Change in substantial holding |
14 June 24 |
Change in substantial holding
×
Change in substantial holding |
12 June 24 |
Application for quotation of securities - IMM
×
Application for quotation of securities - IMM |
12 June 24 |
Cleansing Notice
×
Cleansing Notice |
07 June 24 |
Immutep retail entitlement offer booklet
×
Immutep retail entitlement offer booklet |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.